Biology-inspired microphysiological systems to advance medicines for patient benefit and animal welfare

Abstract

The first microfluidic microphysiological systems (MPS) entered the academic scene more than 15 years ago and were considered an enabling technology to human (patho)biology in vitro and, therefore, provide alternative approaches to laboratory animals in pharmaceutical drug development and academic research. Nowadays, the field generates more than a thousand scientific publications per year. Despite the MPS hype in academia and by platform providers, which says this technology is about to reshape the entire in vitro culture landscape in basic and applied research, MPS approaches have neither been widely adopted by the pharmaceutical industry yet nor reached regulated drug authorization processes at all. Here, 46 leading experts from all stakeholders - academia, MPS supplier industry, pharmaceutical and consumer products industries, and leading regulatory agencies - worldwide have analyzed existing challenges and hurdles along the MPS-based assay life cycle in a second workshop of this kind in June 2019. They identified that the level of qualification of MPS-based assays for a given context of use and a communication gap between stakeholders are the major challenges for industrial adoption by end-users. Finally, a regulatory acceptance dilemma exists against that background. This t4 report elaborates on these findings in detail and summarizes solutions how to overcome the roadblocks. It provides recommendations and a roadmap towards regulatory accepted MPS-based models and assays for patients' benefit and further laboratory animal reduction in drug development. Finally, experts highlighted the potential of MPS-based human disease models to feedback into laboratory animal replacement in basic life science research.

References 91

1. 1.
   Merging organoid and organ-on-a-chip technology to generate complex multi-layer tissue models in a human retina-on-a-chip platform · 2019

   No notice
2. 2.

   Ainslie GR, David M, Ewart L (2019 ). Microphysiological lung models to evaluate the safety of new pharmaceutical modalities: A biopharmaceutical perspective. Lab Chip 19, 3152–3161

   Not in our library10.1039/c9lc00492k

3. 3.
   A Tissue Engineered Blood Vessel Model of Hutchinson-Gilford Progeria Syndrome Using Human iPSC-derived Smooth Muscle Cells · 2017

   Not checked
4. 4.

   Baker M, (2011 ). Tissue models. A living system on a chip. Nature 471, 661–665

   Not in our library10.1038/471661a

5. 5.

   Balls M, Blaauboer B, Brusick D (1990 ). Report and recommendations of the CAAT/ERGATT workshop on the validation of toxicity test procedures. Altern Lab Anim 18, 313–337.

   Not in our library

6. 6.

   Barrile R, van der Meer AD, Park H (2018 ). Organ-on-chip recapitulates thrombosis induced by an anti-CD154 monoclonal antibody: Translational potential of advanced microengineered systems. Clin Pharmacol Ther 104, 1240–1248

   Not in our library10.1002/cpt.1054

7. 7.
   Functional coupling of human pancreatic islets and liver spheroids on-a-chip: Towards a novel human ex vivo type 2 diabetes model · 2017

   Corrected
8. 8.
   Development of a Gut-on-a-Chip Model for High Throughput Disease Modeling and Drug Discovery · 2019

   No notice
9. 9.

   Beilmann M, Boonen H, Czich A (2019 ). Optimizing drug discovery by investigative toxicology: Current and future trends. ALTEX 36, 289–313

   Not in our library10.14573/altex.1808181

10. 10.

    Benam KH, Novak R, Nawroth J (2016a ). Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Syst 3, 456–466

    Not in our library10.1016/j.cels.2016.10.003

11. 11.

    Benam KH, Villenave R, Lucchesi C (2016b ). Small airway-on-a-chip enables analysis of human lung inflammation and drug responses in vitro. Nat Methods 13, 151–157

    Not in our library10.1038/nmeth.3697

12. 12.

    Chou DB, Frismantas V, Milton Y (2018 ). Human bone marrow disorders recapitulated in vitro using organ chip technology. bioRxiv, preprint

    Not in our library10.1101/458935

13. 13.

    Costa PF, Albers HJ, Linssen JE (2017 ). Mimicking arterial thrombosis in a 3D-printed microfluidic in vitro vascular model based on computed tomography angiography data. Lab Chip 17, 2785–2792

    Not in our library10.1039/c7lc00202e

14. 14.

    Desprez B, Dent M, Keller D (2018 ). A strategy for systemic toxicity assessment based on non-animal approaches: The cosmetics Europe long range science strategy programme. Toxicol In Vitro 50, 137–146

    Not in our library10.1016/j.tiv.2018.02.017

15. 15.

    de Graaf MNS, Cochrane A, van den Hil FE (2019 ). Scalable microphysiological system to model three-dimensional blood vessels. APL Bioeng 3, 026105.

    Not in our library10.1063/1.5090986

16. 16.

    EC (2009 ). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. OJ L 342, 59–209. https://bit.ly/2XhN5yU (accessed 12.11.2019).

    Not in our library

17. 17.

    EURL ECVAM – European Reference Laboratory for alternatives to animal testing (2018 ). ECVAM 2018 Survey. https://bit.ly/2wkcsoB (accessed 12.11.2019).

    Not in our library

18. 18.
    Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies · 2018

    No notice
19. 19.

    EMA - European Medicines Agency (2006 ). General Principles Processing Joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) with the framework of the Confidentiality Arrangement. https://bit.ly/2JMX6fw (accessed 12.11.2019).

    Not in our library

20. 20.

    EMA (2013 ). ICH M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. https://bit.ly/39MimfW (accessed 12.11.2019).

    Not in our library

21. 21.

    EMA (2016 ). Guideline on the Principles of Regulatory Acceptance of 3Rs (Replacement, Reduction, Refinement) Testing Approaches. https://bit.ly/2wnDStK (accessed 12.11.2019).

    Not in our library

22. 22.

    EMA (2017 ). First EMA Workshop on Non-animal Approaches in Support of Medicinal Product Development: Challenges and Opportunities for Use of Micro-physiological Systems. https://bit.ly/2JJpKOt (accessed 12.11.2019).

    Not in our library

23. 23.

    Emulate, Inc. (2017 ). FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety Emulate, Inc. press release, 4 11, 2017. https://emulatebio.com/press/fda-collab-agreement-emulate/ (accessed 12.11.2019).

    Not in our library

24. 24.

    EPA - United States Environmental Protection Agency (2018 ). Strategic Plan to Promote the Development and Implementation of Alternative Test Methods Within the TSCA Program EPA Document# EPA-740-R1–8004, 6 22, 2018, Office of Chemical Safety and Pollution Prevention https://www.epa.gov/sites/production/files/2018-06/documents/epa_alt_strat_plan_6-20-18_clean_final.pdf (accessed 12.11.2019).

    Not in our library

25. 25.

    EPA (2019 ). Directive to Prioritize Efforts to Reduce Animal Testing. Memorandum, 9 10, 2019. https://www.epa.gov/sites/production/files/2019-09/documents/image2019-09-09-231249.pdf (accessed 12.11.2019).

    Not in our library

26. 26.

    Ewart L, Fabre K, Chakilam A (2017 ). Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective. Exp Biol Med (Maywood) 242, 1579–1585

    Not in our library10.1177/1535370217715441

27. 27.

    Fitzpatrick S (2017 ). Determining the Predictive Ability of In Vitro Microphysiological Systems to Answer Critical Regulatory Questions. US Food and Drug Administration EMA Workshop, 10 5, 2017. https://bit.ly/34iFQbu (accessed 12.11.2019).

    Not in our library

28. 28.

    Fogel DB (2018 ). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun 11, 156–164

    Not in our library10.1016/j.conctc.2018.08.001

29. 29.

    Foster AJ, Chouhan B, Regan SL (2019 ). Integrated in vitro models for hepatic safety and metabolism: Evaluation of a human liver-chip and liver spheroid. Arch Toxicol 93, 1021–1037

    Not in our library10.1007/s00204-019-02427-4

30. 30.

    Franzen N, van Harten WM, Retel VP (2019 ). Impact of organ-on-a-chip technology on pharmaceutical R&D costs. Drug Discov Today 24, 1720–1724

    Not in our library10.1016/j.drudis.2019.06.003

31. 31.

    Gaio N, van Meer B, Quirós Solano W (2016 ). Cytostretch, an organ-on-chip platform. Micromachines 7, 120

    Not in our library10.3390/mi7070120

32. 32.

    Glieberman AL, Pope BD, Zimmerman JF (2019 ). Synchronized stimulation and continuous insulin sensing in a microfluidic human islet on a chip designed for scalable manufacturing. Lab Chip 19, 2993–3010

    Not in our library10.1039/c9lc00253g

33. 33.

    Hackett JL and Lesko LJ (2003 ). Microarray data - The US FDA, industry and academia. Nat Biotechnol 21, 742–743

    Not in our library10.1038/nbt0703-742

34. 34.

    Halaidych OV, van den Hil F, Mummery CL (2018a ). Microfluidic assay for the assessment of leukocyte adhesion to human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs). J Vis Exp 141, e58678

    Not in our library10.3791/58678

35. 35.

    Halaidych OV, Freund C, van den Hil F (2018b ). Inflammatory responses and barrier function of endothelial cells derived from human induced pluripotent stem cells. Stem Cell Reports 10, 1642–1656

    Not in our library10.1016/j.stemcr.2018.03.012

36. 36.

    Hardwick RN, Betts CJ, Whritenour J (2019 ). Drug-induced skin toxicity: Gaps in preclinical testing cascade as opportunities for complex in vitro models and assays. Lab Chip 20, 199–214

    Not in our library10.1039/c9lc00519f

37. 37.

    Hartung T, Bremer S, Casati S (2004 ). A modular approach to the ECVAM principles on test validity. Altern Lab Anim 32, 467–472

    Not in our library10.1177/026119290403200503

38. 38.

    Hartung T (2007 ). Food for thought … on validation. ALTEX 24, 67–73

    Not in our library10.14573/altex.2007.2.67

39. 39.

    Hartung T, Hoffmann S and Stephens M (2013 ). Mechanistic validation. ALTEX 30, 119–130

    Not in our library10.14573/altex.2013.2.119

40. 40.

    Hartung T, De Vries R, Hoffmann S (2019 ). Toward good in vitro reporting standards. ALTEX 36, 3–17

    Not in our library10.14573/altex.1812191

Cited by papers we hold 3

• New approach methodologies in human regulatory toxicology – Not if, but how and when! · 2023
  No notice
• Shell microelectrode arrays (MEAs) for brain organoids · 2022
  No notice
• Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.